126 related articles for article (PubMed ID: 18829524)
1. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.
Liao YC; Shih YP; Lo SH
Cancer Res; 2008 Oct; 68(19):7718-22. PubMed ID: 18829524
[TBL] [Abstract][Full Text] [Related]
2. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1.
Liao YC; Si L; deVere White RW; Lo SH
J Cell Biol; 2007 Jan; 176(1):43-9. PubMed ID: 17190795
[TBL] [Abstract][Full Text] [Related]
3. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver.
Liao YC; Lo SH
Int J Biochem Cell Biol; 2008; 40(5):843-7. PubMed ID: 17521951
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion-localization of START-GAP1/DLC1 is essential for cell motility and morphology.
Kawai K; Iwamae Y; Yamaga M; Kiyota M; Ishii H; Hirata H; Homma Y; Yagisawa H
Genes Cells; 2009 Feb; 14(2):227-41. PubMed ID: 19170769
[TBL] [Abstract][Full Text] [Related]
5. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.
Kim TY; Healy KD; Der CJ; Sciaky N; Bang YJ; Juliano RL
J Biol Chem; 2008 Nov; 283(47):32762-70. PubMed ID: 18786931
[TBL] [Abstract][Full Text] [Related]
6. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity.
Yuan BZ; Zhou X; Durkin ME; Zimonjic DB; Gumundsdottir K; Eyfjord JE; Thorgeirsson SS; Popescu NC
Oncogene; 2003 Jan; 22(3):445-50. PubMed ID: 12545165
[TBL] [Abstract][Full Text] [Related]
7. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
9. START-GAP2/DLC2 is localized in focal adhesions via its N-terminal region.
Kawai K; Seike J; Iino T; Kiyota M; Iwamae Y; Nishitani H; Yagisawa H
Biochem Biophys Res Commun; 2009 Mar; 380(4):736-41. PubMed ID: 19250640
[TBL] [Abstract][Full Text] [Related]
10. Identifying Cancer-Relevant Mutations in the DLC START Domain Using Evolutionary and Structure-Function Analyses.
Holub AS; Bouley RA; Petreaca RC; Husbands AY
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142932
[TBL] [Abstract][Full Text] [Related]
11. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.
Durkin ME; Ullmannova V; Guan M; Popescu NC
Oncogene; 2007 Jul; 26(31):4580-9. PubMed ID: 17297465
[TBL] [Abstract][Full Text] [Related]
12. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
[TBL] [Abstract][Full Text] [Related]
13. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
Healy KD; Hodgson L; Kim TY; Shutes A; Maddileti S; Juliano RL; Hahn KM; Harden TK; Bang YJ; Der CJ
Mol Carcinog; 2008 May; 47(5):326-37. PubMed ID: 17932950
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
15. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.
Durkin ME; Avner MR; Huh CG; Yuan BZ; Thorgeirsson SS; Popescu NC
FEBS Lett; 2005 Feb; 579(5):1191-6. PubMed ID: 15710412
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
Ullmannova V; Popescu NC
Int J Oncol; 2006 Nov; 29(5):1127-32. PubMed ID: 17016643
[TBL] [Abstract][Full Text] [Related]
17. The Role of Tumor Suppressor DLC-1: Far From Clear.
Liu X; Pan YJ; Zheng JN; Pei DS
Anticancer Agents Med Chem; 2017; 17(7):896-901. PubMed ID: 27604574
[TBL] [Abstract][Full Text] [Related]
18. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DLC-1 gene expression by RNA interference in the colon cancer LoVo cell line.
Jin Y; Tian X; Shang Y; Huang P
Oncol Rep; 2008 Mar; 19(3):669-74. PubMed ID: 18288400
[TBL] [Abstract][Full Text] [Related]
20. Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion.
Hall EH; Daugherty AE; Choi CK; Horwitz AF; Brautigan DL
J Biol Chem; 2009 Dec; 284(50):34713-22. PubMed ID: 19826001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
